Halo Labs, a San Francisco, CA-based life science instrumentation company developing tools for biologics researchers, closed a $5.6M Series B financing.
The round was led by Research Corporation Technologies (RCT). Additional backers included BroadOak Capital Partners, BioAdvance, the BenFranklin Technology Partners of South Eastern Pennsylvania, Paul McEwan, and other current employees.
The company intends to use the funds to commercialize its Horizon® subvisible particle analysis instrument and the continued development of its product pipeline.
Led by Robert Wicke, CEO, Halo Labs provides Horizon®, which enables for the first time high-throughput, low-volume subvisible particle analysis. The Horizon instrument performs high-throughput subvisible particle analysis using volumes as low as 25 µL.
The company also announced that Dr. Joseph Keegan has been named Executive Chairman of the Board of Directors.